Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34366212.
- Also identified by DOI 10.1016/j.eururo.2021.07.019.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We discuss results from the Checkmate-274 and IMvigor010 trials on adjuvant immune checkpoint inhibitor (ICI) therapy in muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC), and conclude that adjuvant ICI (nivolumab but not atezolizumab) should be considered for patients with resected high-risk MIBC, especially for those who have received NAC.
Medical subject headings
- Immune Checkpoint Inhibitors
- Urinary Bladder Neoplasms